These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 10926440)

  • 1. Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen.
    Xuan D; Lu JF; Nicolau DP; Nightingale CH
    Int J Antimicrob Agents; 2000 Aug; 15(3):185-91. PubMed ID: 10926440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing.
    Xuan D; Nicolau DP; Nightingale CH
    Int J Antimicrob Agents; 2004 Mar; 23(3):291-5. PubMed ID: 15164971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tobramycin disposition in ICU patients receiving a once daily regimen: population approach and dosage simulations.
    Conil JM; Georges B; Ruiz S; Rival T; Seguin T; Cougot P; Fourcade O; Pharmd GH; Saivin S
    Br J Clin Pharmacol; 2011 Jan; 71(1):61-71. PubMed ID: 21143502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of tobramycin.
    Aarons L; Vozeh S; Wenk M; Weiss P; Follath F
    Br J Clin Pharmacol; 1989 Sep; 28(3):305-14. PubMed ID: 2789924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
    Hennig S; Norris R; Kirkpatrick CM
    Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.
    Downes KJ; Dong M; Fukuda T; Clancy JP; Haffner C; Bennett MR; Vinks AA; Goldstein SL
    J Antimicrob Chemother; 2017 Jan; 72(1):254-260. PubMed ID: 27585963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population kinetics of tobramycin in neonates.
    Falcão AC; Buelga DS; Méndez ME; García MJ; Pardo M
    Ther Drug Monit; 2001 Jun; 23(3):202-8. PubMed ID: 11360026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients.
    Lee C; Walker SAN; Walker SE; Seto W; Simor A; Jeschke M
    Burns; 2017 Dec; 43(8):1766-1774. PubMed ID: 28647460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
    Massie J; Cranswick N
    J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules.
    Sánchez-Alcaraz A; Vargas A; Quintana MB; Rocher A; Querol JM; Poveda JL; Hermenegildo M
    J Clin Pharm Ther; 1998 Oct; 23(5):367-73. PubMed ID: 9875685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.
    Zhang J; Xu JF; Liu YB; Xiao ZK; Huang JA; Si B; Sun SH; Xia QM; Wu XJ; Cao GY; Shi YG; Zhang YY
    J Infect Chemother; 2009 Oct; 15(5):293-300. PubMed ID: 19856067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults.
    Tod M; Lortholary O; Seytre D; Semaoun R; Uzzan B; Guillevin L; Casassus P; Petitjean O
    Antimicrob Agents Chemother; 1998 Apr; 42(4):849-56. PubMed ID: 9559795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens.
    Barletta JF; Johnson SB; Nix DE; Nix LC; Erstad BL
    J Trauma; 2000 Nov; 49(5):869-72. PubMed ID: 11086778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bicompartmental kinetics of tobramycin analysed with a wide range of covariates.
    Inclan G; Suarez E; Calvo R; Aguirre C; Macheras P; Gazouli M; Lukas JC
    Int J Antimicrob Agents; 2005 Oct; 26(4):304-11. PubMed ID: 16168626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NONMEM and NPEM2 population modeling: a comparison using tobramycin data in neonates.
    de Hoog M; Schoemaker RC; van den Anker JN; Vinks AA
    Ther Drug Monit; 2002 Jun; 24(3):359-65. PubMed ID: 12021626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gentamicin and tobramycin pharmacokinetics in pediatric bone marrow transplant patients.
    Jacobson PA; West NJ; Price J; Hutchinson RJ
    Ann Pharmacother; 1997 Oct; 31(10):1127-31. PubMed ID: 9337435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm.
    Touw DJ; Vinks AA; Neef C
    Pharm World Sci; 1997 Jun; 19(3):142-51. PubMed ID: 9259030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration.
    Dupuis LL; Sung L; Taylor T; Abdolell M; Allen U; Doyle J; Taddio A
    Pharmacotherapy; 2004 May; 24(5):564-73. PubMed ID: 15162890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation.
    Downes KJ; Grim A; Shanley L; Rubenstein RC; Zuppa AF; Gastonguay MR
    Antimicrob Agents Chemother; 2022 May; 66(5):e0237721. PubMed ID: 35481751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.